Charles River Laboratories’ CEO said the company expects more cell and gene therapy manufacturers to break away from vertically integrated models, following Charles River’s decision to shed its cell and gene therapy manufacturing unit. The comment underscores how manufacturing complexity and cost structure are driving strategic separation across the CRO/CDMO landscape. Separately, Anova scaled a virtual urology clinical-trial network to 500 sites using its AnovaOS platform, aiming to improve start-up speed, recruitment, remote monitoring, and adverse event reporting. For sponsors, digitally supported networks are increasingly positioned as a way to compress timelines while keeping trial operations standardized.